Ultivue brings in $5m through Arch

Ultivue, a spinout of Harvard University commercialising microscopy technology, has secured $5.15m in its series A.

The round into the US-based company, Ultivue’s first, was led Arch Venture Partners with support from Swiss entrepreneur Hansjörg Wyss and a number of private investors. 

Ultivue is developing a technique for detailed image collective for life sciences research and medical diagnostics. Daavid Walt, co-founder of Ultivue, said: “Ultivue’s technology is revolutionary because it makes very high resolution microscopy experiments possible and enables researchers to look at numerous biomolecules simultaneously in a single sample.”

Keith Crandell, co-founder and managing director of Arch Venture Partners, added: “The novelty and simplicity of Ultivue’s technology and its compatibility with a huge installed base of existing microscopes will bring enormous value to the life sciences.  We are thrilled to support the company as it transforms super resolution microscopy and enables new avenues of biomedical discovery and digital pathology.”